Revelation Biosciences effects 1-for-30 reverse stock split, ~210K shares outstanding

REVELATION BIOSCIENCES, INC.

Stockholders approved reverse split at Jan 17 special meeting; board set ratio at 1-for-30.
Reverse split effective 12:01 a.m. ET on Jan 25, 2024; common stock continues trading under REVB.
Post-split shares outstanding ~209,911; no fractional shares, rounding up to whole shares.
Outstanding equity awards and warrants proportionally adjusted for the 1-for-30 ratio.
New CUSIP for common stock: 76135L507.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

REVELATION BIOSCIENCES, INC.: Filed Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation to effect a 1-for-30 reverse stock split, effective January 25, 2024 (effective 2024-01-25).

Change: charter amendment
Effective: 2024-01-25

Exact text from the filing

On January 22, 2024, the Company filed a Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on January 25, 2024 with a ratio of 1-for-30 (the “Reverse Split”).

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-006510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.